Request Demo

Last update 26 Aug 2026

Fentanyl Citrate

Last update 26 Aug 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Abstral Sublingual, E-Fen Buccal, Fentanyl citrate (JP17/USP)

+ [33]

Target

μ opioid receptor

Action

agonists

Mechanism

μ opioid receptor agonists(Mu opioid receptor agonists)

Therapeutic Areas

Nervous System DiseasesUrogenital DiseasesOther Diseases

Active Indication

Breakthrough PainCancer PainHyperemesis Gravidarum+ [1]

Inactive Indication

Anemia, Sickle CellBurnsChronic Pain+ [9]

Originator Organization

Rising Pharmaceuticals, Inc.

Active Organization

Teikoku Seiyaku Co. Ltd.

Istituto Gentili Srl

Phoenix Labs

+ [5]

Inactive Organization

Sentynl Therapeutics, Inc.

BTcP Pharma LLC

Cephalon LLC

+ [6]

License Organization

Kunwha Pharmaceutical Co., Ltd.

Daiichi Sankyo Co., Ltd.

Collegium Pharmaceutical, Inc.

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (19 Feb 1968),

Anesthesia

Regulation-

Structure/Sequence

Molecular FormulaC28H36N2O8

InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N

CAS Registry990-73-8

1,361

Clinical Trials associated with Fentanyl Citrate

NCT07435493

/ Not yet recruitingNot ApplicableIIT

Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstructive Sleep Apnea

Emphasize that the usage of multimodal analgesia in managing perioperative pain in children with mild to moderate Obstructive Sleep Apnea undergoing adenotonsillectomy may achieve the same efficacy of fentanyl with less respiratory complications and less opioid-related side effects.

Start Date30 Nov 2026

Sponsor / Collaborator

Ain Shams University

NCT07112430

/ Not yet recruitingPhase 1/2IIT

Intranasal Fentanyl to Reduce Pain Intensity Associated With Retinopathy of Prematurity Screening in Preterm Infants: A Randomized Control Trial

The goal of this clinical trial is to learn whether intranasal fentanyl (a pain medicine given as a nasal spray) can reduce pain and is safe to use during routine eye examinations for retinopathy of prematurity (ROP) in preterm infants. ROP is an eye condition that can affect babies born too early and requires regular eye examinations. The main questions this study aims to answer are: Does intranasal fentanyl lower pain during ROP screening? Is intranasal fentanyl safe for preterm infants? Researchers will compare intranasal fentanyl with a placebo (a saltwater spray that contains no medicine) to determine whether the medicine lowers pain during ROP screening.
Participants will receive either intranasal fentanyl or placebo before their routine ROP eye examination, in addition to the standard comfort measures normally used during the procedure. Researchers will measure participants' pain and monitor their heart rate, oxygen levels, and any side effects during and after the examination.

Start Date09 Sep 2026

Sponsor / Collaborator

IWK Health Centre

[+3]

NCT07739641

/ Not yet recruitingNot ApplicableIIT

A COMPARATIVE STUDY BETWEEN OPIOID-FREE GENERAL ANAESTHESIA AND OPIOID-BASED GENERAL ANAESTHESIA ON THE QUALITY OF RECOVERY IN PATIENTS UNDERGOING ELECTIVE LAPAROSCOPIC HYSTRECTOMY: A Randomized Trial

the intent of this study To compare the efficacy of opioid free general anaesthesia versus opioid based general anaesthesia to achieve enhanced recovery regarding post-operative pain and post-operative nausea and vomiting episodes in patients undergoing elective laparoscopic hysterectomy

Start Date22 Aug 2026

Sponsor / Collaborator

Ain Shams University

100 Clinical Results associated with Fentanyl Citrate

100 Translational Medicine associated with Fentanyl Citrate

100 Patents (Medical) associated with Fentanyl Citrate

6,790

Literatures (Medical) associated with Fentanyl Citrate

01 Sep 2026·BRITISH JOURNAL OF ANAESTHESIA

Effects of fentanyl on diaphragm muscle force in patients undergoing knee arthroplasty: a randomised double-blind clinical trial

Article

Author: Jahanian, Sepideh ; Anderson, Brenda K ; Stoltenberg, Anita D ; Schroeder, Darrell R ; Gransee, Heather M ; Knoll, Kate M ; Urban, Matthew W ; Martin, Beth A ; Mantilla, Carlos B ; Panchamia, Jason K

BACKGROUND:

Opioids exert important negative effects on respiration, evident across a range of behaviours. The present study evaluated whether fentanyl administration decreases diaphragm muscle forces across levels of inspiratory loading in adult patients undergoing elective knee arthroplasty surgery.

METHODS:

Adult patients undergoing elective knee arthroplasty with no pulmonary pathology were randomly assigned to a fentanyl dose (25, 50, or 100 μg) in a double-blind, single-institution clinical trial. Ultrasound-based shear wave elastography was used to measure diaphragm Young's modulus (E). The primary outcome was change in the difference in E achieved across levels of inspiratory loading (E range) before randomisation and 10 min post-fentanyl (ΔE range) as a measure of fentanyl-induced changes in diaphragm force-generating capacity.

RESULTS:

Sixty-nine patients (average age 69 yr) were randomised, with final data analysis in 22, 22, and 19 patients from the 25, 50, and 100 μg groups, respectively. The ΔE range was compared across dose groups using analysis of covariance, with the pretreatment E range included as the covariate. The estimated treatment effect (95% confidence interval) for 50 μg vs 25 μg, and for 100 μg vs 25 μg was -0.7 (-9.5, 8.1) and -5.3 (-14.1, 3.6), respectively. There was no statistically significant effect of fentanyl on ΔE range (P=0.432).

CONCLUSIONS:

Fentanyl did not reduce the E range generated by the diaphragm muscle during inspiratory pressure-threshold loading, possibly reflecting relatively low levels of inspiratory loading or the presence of a fentanyl effect even at the lowest dose used (25 μg) in this older patient population.

CLINICAL TRIALS ID:

NCT05856136.

01 May 2026·Journal of perioperative practice

Efficacy of the intravenous formulation of fentanyl citrate administered orally as premedication in paediatric patients undergoing open cardiac surgery

Article

Author: Islam Mohamed Elbardan ; Ahmed Galaleldin Yacout ; Ibrahim Mabrouk Mabrouk ; Ahmed Sayed Shehab

Background::

Recently, fentanyl has become prevalent as a sedative premedication.

Methods::

A non-inferiority parallel design quadruple-blinded randomised controlled trial of 1- to 7-year-old children scheduled for elective cardiac surgery was conducted. Participants were assigned a 1:1 allocation ratio to a control group ( n = 50) given a parenteral formulation of midazolam 0.5 mg/kg and an intervention group ( n = 50) given a parenteral formulation of fentanyl 10 μg/kg 30 min before admission to the operating room.

Results::

Fentanyl was shown to be inferior when compared to midazolam during inhalational induction but not in the ‘after premedication’ and ‘during separation’ periods. A lower percentage of children disliked the medication in the fentanyl group.

Conclusions::

A parenteral formulation of fentanyl can be a satisfactory alternative when given orally as a sedative pre-anaesthetic medication in paediatric cardiac surgery before admission to the operating room.

01 Apr 2026·THORAX

Efficacy of fentanyl buccal tablet and morphine for exertional dyspnoea in patients with cancer: a double-blind, placebo-controlled, randomised clinical trial

Article

Author: Penny Stanton ; David Hui ; Eduardo Bruera ; Raul Laureano ; Kristofer Jennings ; Soraira Pacheco ; Linh Nguyen ; Vera de la Cruz ; Donald Mahler ; Amy Ontai

Introduction:

Exertional dyspnoea is highly debilitating. Previous single-dose studies found that prophylactic administration of fentanyl buccal tablet (FBT) improved exertional dyspnoea. In this randomised trial, we compared daily use of prophylactic FBT, oral morphine and placebo on exertional dyspnoea over 14 days.

Methods:

This parallel, double-blind, randomised clinical trial enrolled opioid-tolerant patients with cancer and exertional dyspnoea. After a 5-day observation period, patients were randomised (1:1:1) to receive FBT, morphine or placebo 30 min before daily structured activity for 14 days. Shuttle walk tests (SWTs) were conducted on days 1/5/8/12/15/19. The primary outcome was change in modified Borg Scale dyspnoea intensity during SWTs from day 5 to day 19, analysed using a mixed effects model with treatment, time and treatment×time interaction. SWT distance was a key secondary outcome.

Results:

67 patients were enrolled and 56 (84%) were randomised. Over the 14-day blinded phase, we observed a significant decrease in the magnitude of dyspnoea intensity change during the SWTs in all three groups, with no significant difference by treatment group (slope change from day 5 to day 19: FBT −2.2 (95% CI −2.9 to –1.6); morphine −1.9 (95% CI −2.7 to –1.2); placebo −2.2 (95% CI −3 to –1.4); time effect p<0.001, treatment×time effect p=0.79). SWT distance increased significantly over time (FBT +93 m; morphine +84 m; placebo +76 m) but did not differ by treatment (p=0.71). Few adverse events were reported.

Conclusion:

All three groups reported less dyspnoea while walking farther; however, no difference was detected between opioids and placebo. These findings should be considered preliminary given the underpowered sample.

Trial registration number:

NCT04188418 .

News (Medical) associated with Fentanyl Citrate

14 Aug 2026

·www.biospace.com

Lifeloc Reports Second Quarter 2026 Results

WHEAT RIDGE, CO / ACCESS Newswire / August 13, 2026 / Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2026. Second Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.445 million in the second quarter of 2026, resulting in a quarterly net loss of $(134) thousand, or $(0.05) per diluted share. These results compare to net revenue of $2.219 million and quarterly net loss of $(394) thousand, or $(0.14) per diluted share in the second quarter of 2025. Revenue for the quarter grew 10% versus the second quarter last year. Six-month net revenues of $4.739 million and a net loss of $(287) thousand, or $(0.10) per diluted share, compared to net revenue of $4.496 million and a net loss of $(686) thousand, or $(0.25) per diluted share, for the same period in 2025. Total gross margin in the second quarter rose to 45% versus 42% for the same quarter last year. For the first six months of 2026, gross margin was 44% versus 41% for the same period last year, with price increases and a favorable product mix contributing to the higher margins. The research and development investment for the quarter remained high at $560 thousand, primarily for SpinDetect™ analyzer development, resulting in the current period loss. Alcohol Detection Products We believe our core alcohol detection product line-up is strong. The L-series LX9 and LT7 units have features and performance that drive market penetration by meeting previously unaddressable market needs, such as smart phone pairing, wider temperature use ranges and fast customization that incorporates local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as the latest AS 3547:2019 standards for Breath Alcohol Detectors from SAI Global (formerly Standards Australia International). Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal ® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and has contributed to market share gains across the board, especially for our workplace Phoenix ® 6.0 BT and EV 30 devices. SpinDetect™ Analyzer Platform We believe our most significant long-term opportunity lies at the intersection of the global need for rapid, quantitative drug detection and our proven expertise in portable testing instrumentation. Our SpinDetect ™ Centrifugal Drug Analyzer - sometimes referred to as "Lab on a Disk" - is designed to address this need, enabling rapid, on-site, quantitative drug testing for use at roadside, in emergency rooms, forensic labs, and workplace testing sites. We have demonstrated the platform's ability to effectively detect delta-9-THC, cocaine, fentanyl, amphetamine/methamphetamine, morphine, MDMA, and benzodiazepines from oral fluid. We have validated our test results against liquid chromatography-mass spectrometry (LC-MS) - the definitive laboratory standard - using real-world human saliva samples, confirming a limit of detection of approximately 10 ng/ml. We have completed the design of the SpinDetect ™ microfluidic disk, with all analytical chemistry now occurring on the disk after sample introduction. Disk design represented the primary technical challenge throughout the project, requiring specialized outside expertise and multiple design iterations. Disks have been molded and assays loaded for evaluation, with final component and process optimization ongoing. Reader hardware, firmware, drug assays, and reagent handling have been developed in parallel and are substantially complete. We will be initiating beta testing of the oral-fluid analyzer, focused on delta-9-THC detection using a prototype reader, under a signed beta-testing agreement, and are now targeting a limited commercial launch in Q1 of 2027. "It is great to see assays performed with all the chemistry occurring on the disk. With our second dispensing robot scheduled for delivery later this month, we are moving closer to production," commented Dr. Wayne Willkomm, President and CEO. "Oral fluid drug screening will only be the first launching application of this technology platform. We expect subsequent releases to expand to additional drug panels and to samples collected from blood and breath, as well as to other applications, including select non-drug applications such as food pathogen detection." Financing Update During the quarter, Lifeloc closed on $500,000 of financing, securing a loan from our Chairman of the Board, who also serves as our Chief Financial Officer. This loan is detailed in our 8-K filing of May 8, 2026, and the key terms are 10.5% interest, adjustable upward based on the prime rate, interest only payments in 2026, followed by monthly payments that will result in the loan being fully paid in 5 years, and no prepayment penalty. The loan is secured by all of our assets. After exploring multiple financing options, the Company determined these terms were more favorable than alternatives available from commercial sources. About Lifeloc Technologies Lifeloc Technologies, Inc. (OTCID: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, . Forward Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, market liquidity for our shares, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings . Phoenix ® and Easycal ® are registered trademarks of Lifeloc Technologies, Inc. SpinDetect ™ is a trademark of Lifeloc Technologies, Inc. Amy Evans Lifeloc Technologies, Inc. (303) 431-9500 LIFELOC TECHNOLOGIES, INC. Condensed Balance Sheets (Unaudited) ASSETS CURRENT ASSETS: June 30, 2026 December 31, 2025 Cash and cash equivalents $ 908,208 $ 746,001 Accounts receivable, net 826,715 772,380 Inventories, net 2,839,516 2,633,614 Federal and state income taxes receivable 55,981 55,981 Prepaid expenses and other 146,901 60,825 Total current assets 4,777,321 4,268,801 PROPERTY, PLANT AND EQUIPMENT: Land 317,932 317,932 Building 1,928,795 1,928,795 Real-time Alcohol Detection And Recognition equipment and software 569,448 569,448 Production equipment, software and space modifications 1,366,539 1,366,539 Office equipment, software and space modifications 197,686 197,686 Sales and marketing equipment and space modifications 230,543 225,173 Research and development equipment, software and space modifications 1,247,201 1,213,195 Research and development equipment, software and space modifications not in service - 19,595 Less accumulated depreciation (3,670,607 ) (3,538,455 ) Total property and equipment, net 2,187,537 2,299,908 OTHER ASSETS: Patents, net 67,229 71,039 Deposits and other 46,820 46,820 Total other assets 114,049 117,859 Total assets $ 7,078,907 $ 6,686,568 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 501,118 $ 301,627 Term loans payable, current portion 94,774 54,850 Subordinated debentures payable, current portion 35,697 33,371 Customer deposits 20,336 25,694 Accrued expenses 350,141 321,112 Deferred revenue, current portion 50,464 53,716 Product warranty reserve 46,500 46,500 Total current liabilities 1,099,030 836,870 TERM LOANS PAYABLE, net of current portion and debt issuance costs 1,030,364 1,058,426 TERM LOAN PAYABLE (Related Party), net current portion and debt issuance costs 460,922 - SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs 662,901 681,343 DEFERRED REVENUE, net of current portion 8,955 6,151 Total liabilities 3,262,172 2,582,790 COMMITMENTS AND CONTINGENCIES (Note 6) STOCKHOLDERS' EQUITY: Common stock, no par value; 50,000,000 shares authorized, 2,752,616 shares outstanding 5,934,314 5,934,314 Accumulated deficit (2,117,579 ) (1,830,536 ) Total stockholders' equity 3,816,735 4,103,778 Total liabilities and stockholders' equity $ 7,078,907 $ 6,686,568 LIFELOC TECHNOLOGIES, INC. Condensed Statements of Profit (Loss) (Unaudited) Three Months Ended June 30, REVENUES: 2026 2025 Product sales $ 2,434,697 $ 2,191,260 Royalties 10,260 19,800 Rental income - 8,316 Total 2,444,957 2,219,376 COST OF SALES 1,352,431 1,294,777 GROSS PROFIT 1,092,526 924,599 OPERATING EXPENSES: Research, development, and sustaining engineering 560,281 623,262 Sales and marketing 320,968 339,528 General and administrative 314,853 340,074 Total 1,196,102 1,302,864 OPERATING (LOSS) (103,576 ) (378,265 ) OTHER INCOME (EXPENSE): Interest income 8,856 10,931 Interest expense (39,610 ) (26,305 ) Total (30,754 ) (15,374 ) NET (LOSS) BEFORE PROVISION FOR TAXES (134,330 ) (393,639 ) BENEFIT FROM FEDERAL AND STATE INCOME TAXES - - NET (LOSS) $ (134,330 ) $ (393,639 ) NET (LOSS) PER SHARE, BASIC $ (0.05 ) $ (0.14 ) NET (LOSS) PER SHARE, DILUTED $ (0.05 ) $ (0.14 ) WEIGHTED AVERAGE SHARES, BASIC 2,752,616 2,752,616 WEIGHTED AVERAGE SHARES, DILUTED 2,752,616 2,752,616 LIFELOC TECHNOLOGIES, INC. Condensed Statements of Profit (Loss) (Unaudited) Six Months Ended June 30, REVENUES: 2026 2025 Product sales $ 4,724,456 $ 4,454,307 Royalties 14,313 25,471 Rental income - 16,632 Total 4,738,769 4,496,410 COST OF SALES 2,659,169 2,663,245 GROSS PROFIT 2,079,600 1,833,165 OPERATING EXPENSES: Research, development, and sustaining engineering 974,726 1,092,942 Sales and marketing 634,197 674,084 General and administrative 702,255 724,952 Total 2,311,178 2,491,978 OPERATING (LOSS) (231,578 ) (658,813 ) OTHER INCOME (EXPENSE): Interest income 15,387 23,288 Interest expense (70,852 ) (50,800 ) Total (55,465 ) (27,512 ) NET (LOSS) BEFORE PROVISION FOR TAXES (287,043 ) (686,325 ) BENEFIT FROM FEDERAL AND STATE INCOME TAXES - - NET (LOSS) $ (287,043 ) $ (686,325 ) NET (LOSS) PER SHARE, BASIC $ (0.10 ) $ (0.25 ) NET (LOSS) PER SHARE, DILUTED $ (0.10 ) $ (0.25 ) WEIGHTED AVERAGE SHARES, BASIC 2,752,616 2,723,768 WEIGHTED AVERAGE SHARES, DILUTED 2,752,616 2,723,768 Lifeloc Technologies, Inc. Condensed Statements of Changes in Stockholders' Equity (Unaudited) For the Three and Six Months Ended June 30, 2026 and 2025 2026 Common Stock Shares Common Stock Amount Accumulated Deficit Total Beginning balance, December 31, 2025 2,752,616 $ 5,934,314 $ (1,830,536 ) $ 4,103,778 Net (loss) - - (152,713 ) (152,713 ) Ending balance, March 31, 2026 2,752,616 5,934,314 (1,983,249 ) 3,951,065 Net (loss) - - (134,330 ) (134,330 ) Ending balance, June 30, 2026 2,752,616 $ 5,934,314 $ (2,117,579 ) $ 3,816,735 2025 Common Stock Shares Common Stock Amount Accumulated Deficit Total Beginning balance, December 31, 2024 2,664,116 $ 5,586,014 $ 639,863 $ 6,225,877 Issuance of shares from option exercise 88,500 336,300 - 336,300 Warrants issued with subordinated debenture - 12,000 - 12,000 Net (loss) - - (292,686 ) (292,686 ) Ending balance, March 31, 2025 2,752,616 5,934,314 347,177 6,281,491 Net (loss) - - (393,639 ) (393,639 ) Ending balance, June 30, 2025 2,752,616 $ 5,934,314 $ (46,462 ) $ 5,887,852 LIFELOC TECHNOLOGIES, INC. Condensed Statements of Cash Flows (Unaudited) Six Months Ended June 30, CASH FLOWS FROM OPERATING ACTIVITIES: 2026 2025 Net (loss) $ (287,043 ) $ (686,325 ) Adjustments to reconcile net income (loss) to net cash (used in) operating activities- Depreciation and amortization 135,962 216,419 Amortization of debt issuance costs 12,103 5,886 Changes in operating assets and liabilities- Accounts receivable (54,335 ) (33,189 ) Inventories (205,902 ) 7,645 Federal and state income taxes receivable - 25,029 Prepaid expenses and other (86,076 ) (120,034 ) Deposits and other - - Accounts payable 199,491 141,419 Customer deposits (5,358 ) (6,186 ) Accrued expenses 29,029 55,416 Deferred revenue (448 ) 4,344 Net cash (used in) operating activities (262,577 ) (389,576 ) CASH FLOWS (USED IN) INVESTING ACTIVITIES: Purchases of sales and marketing equipment (5,370 ) (5,462 ) Purchases of research and development equipment, software and space modifications (14,411 ) (17,348 ) Purchases of research and development equipment, software and space modifications not in service - (219,441 ) Net cash (used in) investing activities (19,781 ) (242,251 ) CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES: Principal payments made on term loan (28,290 ) (27,469 ) Proceeds from issuance of subordinated debenture - 75,000 Proceeds (related party) from issuance of term loan 500,000 - Principal payments made on subordinated debentures (27,145 ) - Proceeds from issuance of shares from option exercise - 336,300 Net cash provided from (used in) financing activities 444,565 383,831 NET INCREASE (DECREASE) IN CASH 162,207 (247,996 ) CASH, BEGINNING OF PERIOD 746,001 1,243,746 CASH, END OF PERIOD $ 908,208 $ 995,750 SUPPLEMENTAL INFORMATION: Cash paid for interest $ 59,264 $ 44,914 Cash paid for income tax $ - $ 150 Income tax refund received - $ 25,179 Non-cash financing and investing activities: warrants issued with subordinated debenture $ - $ 12,000 SOURCE: Lifeloc Technologies, Inc. View the original press release on ACCESS Newswire

Financial Statement

04 Aug 2026

·www.biospace.com

PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(News - August 4, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") , is pleased to announce that, further to its news releases dated July 27, 2026, June 12, 2026, May 12, 2026 and April 22, 2026 (the " Prior News Releases "), it has closed a fourth tranche (the " Fourth Tranche ") of its previously announced non-brokered private placement (the " Offering "), which Fourth Tranche consisted of the issuance of 8,600,000 units (each, a " Unit ") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $215,000. The Company closed an initial tranche on May 12, 2026 consisting of the issuance of 13,600,000 Units for gross proceeds of $340,000, a second tranche on June 12, 2026 consisting of the issuance of 9,800,000 Units for gross proceeds of $245,000 and a third tranche on July 27, 2026 consisting of the issuance of 8,000,000 Units for gross proceeds of $200,000. The Company has received aggregate proceeds of $1,000,000 from all tranches. Each Unit is comprised of one (1) common share (each, a " Share ") in the capital of the Company and one-half (1/2) of one Share purchase warrant (each whole warrant, a " Warrant "). Each Warrant entitles the holder thereof to purchase an additional Share (each, a " Warrant Share ") at an exercise price of $0.05 per Warrant Share for a period of two years from the closing of the Fourth Tranche (the " Fourth Tranche Closing "), subject to an acceleration right, whereby the expiry date of the Warrants may be accelerated if the daily closing price of the Shares equals or exceeds $0.08 per Share (the " Acceleration Price ") on the Canadian Securities Exchange (" CSE ") (or such other recognized securities exchange on which the Shares may then trade) for a minimum of ten consecutive trading days, in which event the Company may accelerate the expiry of the Warrants by giving notice via news release and, in such case, all of the then unexercised Warrants will expire on the 30 th day after the date on which the news release is disseminated (the " Acceleration Right "). The Acceleration Price was incorrectly referenced as $0.10 in the Prior News Releases where it should have been referenced as $0.08. The correct Acceleration Price for all tranches is $0.08 per Share. In connection with the Fourth Tranche Closing, the Company paid a cash fee of $17,200 and issued 688,000 finder's warrants (each, a " Finder's Warrant ") to one eligible finder. The Finder's Warrants are exercisable into one additional Share at an exercise price of $0.05 per Share for two years from the Fourth Tranche Closing, subject to the Acceleration Right. The Company intends to use the aggregate gross proceeds of the Fourth Tranche for short loan repayments, audit, accounting and legal fees, patents and further studies and analysis of rodents and tissues and general working capital purposes. All securities issued in relation to the Fourth Tranche are subject to a hold period expiring four months and one day after the Fourth Tranche Closing, in accordance with applicable securities laws. The securities issued under the Offering, including those in the Fourth Tranche, have not been and will not be registered under the United States Securities Act of 1933 , as amended (the " Securities Act "), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About PreveCeutical PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook . On behalf of the Board of Directors of PreveCeutical Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact: Stephen Van Deventer: +1 604 306 9669 Or Investor Relations ir@preveceutical.com Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the use of proceeds of the Offering. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that the proceeds of the Offering may not be used as stated in this news release and those additional risks set out in the Company's public documents filed on SEDAR+ at . Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES To view the source version of this press release, please visit

Clinical Study

23 Jun 2026

·www.globenewswire.com

SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences

NORTH PALM BEACH, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE American: SRXH) (the "Company", or “SRX”) today announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, such as fentanyl. ARMR’s lead product, ARMR-100, recently announced it has successfully generated an anti-fentanyl immune response in humans and showed favorable safety data. This marks a critical milestone in the company's path toward demonstrating that this response can protect against fentanyl. ARMR-100 is being designed to work with the body to generate a protective immune response. The product, in a Phase 1/2 clinical trial, produces anti-fentanyl antibodies capable of binding to lethal synthetic drugs. Once the antibodies bind to the synthetic drug target, such as fentanyl, the drug is prevented from entering the brain. If the molecule is prevented from reaching the brain, then the downstream effects that lead to overdose may also be prevented. ARMR-100 is in development to be the first long-lasting preventive medication against fentanyl, with the goal that the product endures for 6-12 months in healthy adults. The next phase is evaluating protection against fentanyl, currently on track to begin later in 2026. "I want to thank the entire team at SRX Global for their investment and belief in our vision, turning what many called impossible into a reality," said Collin Gage, CEO of ARMR Sciences. "Our recently announced positive early results are a testament to the deeply experienced team of scientists, researchers, and medical professionals we have assembled. While there is still important work ahead, we believe today's milestone further validates our approach and reinforces our confidence in the path forward as we continue advancing a potential solution that could save countless lives. We look forward to a great partnership with SRX going forward." About ARMR SciencesARMR Sciences is a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, including fentanyl, and other emerging chemical threats. The company's lead product, ARMR-100, is designed to generate a protective immune response that produces antibodies capable of binding synthetic molecules and blocking them from reaching the brain. For more information, visit https://armrsciences.com Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "intend," "aim," "plan," "may," "could," "target," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law. Company ContactSRX Global, Inc.Kent Cunningham, Chief Executive Officer Investor Relations ContactKCSA Strategic CommunicationsValter Pinto, Managing Director212-896-1254srx@kcsa.com

ImmunotherapyIND

100 Deals associated with Fentanyl Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D01399	Fentanyl Citrate	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	United States	Adalvo Ltd.	16 Jul 2009
Breakthrough Pain	European Union	Phoenix Labs	04 Apr 2008
Breakthrough Pain	Iceland	Phoenix Labs	04 Apr 2008
Breakthrough Pain	Liechtenstein	Phoenix Labs	04 Apr 2008
Breakthrough Pain	Norway	Phoenix Labs	04 Apr 2008
Cancer Pain	United States	Cephalon LLC	04 Nov 1998
Hyperemesis Gravidarum	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Anesthesia	United States	Rising Pharmaceuticals, Inc.	19 Feb 1968

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 3	Italy	L. Molteni & C. dei F.lli Alitti Società di Esercizio SpA	01 Sep 2014
Respiratory Insufficiency	Phase 3	-	BioDelivery Sciences International, Inc.	01 Jun 2008
Chronic Pain	Phase 3	United States	Cephalon LLC	01 Dec 2006
Complex Regional Pain Syndromes	Phase 3	United States	Cephalon LLC	01 Sep 2005
Low Back Pain	Phase 3	United States	Cephalon LLC	01 Sep 2005
Neuralgia	Phase 3	United States	Cephalon LLC	01 Sep 2005
Neuralgia, Postherpetic	Phase 3	United States	Cephalon LLC	01 Sep 2005
Neoplasms	Phase 3	-	Cephalon LLC	01 Jun 2004
Dyspnea, Paroxysmal	Phase 2	Germany	Teva Branded Pharmaceutical Products R&D LLC	01 Mar 2013
Lung Cancer	Phase 2	Germany	Teva Branded Pharmaceutical Products R&D LLC	01 Mar 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05856136 (Pubmed \| Br J Anaesth)	Phase 4	Pain	63	Fentanyl 25 μg	wxberrpdyz(ycbfhxbfvt): Difference = -0.7 (95.0% CI, -9.5 to 8.1)	Positive	01 Jul 2026
				Fentanyl 50 μg
Pubmed \| Indian J Pediatr	Not Applicable	Sedation	75	Ketamine-Fentanyl	jabopycqlb(ihwgexgzyi) = No participants developed bradycardia, hypotension, apnea, laryngospasm, or deep desaturation. mzldrgmrce (xniivzyzvt ) View more	Negative	01 Apr 2026
				Ketamine-Midazolam
NCT03476369 (FACTPCI, CTgov)	Phase 4	-	45	Fentanyl+Ticagrelor 90Mg Tablet (Fentanyl and Crushed Ticagrelor)	qqcjiwzbey(qkpundrpkt) = fvmzyxnwdq ubuwzwdbde (sbvsgjkvwq, zwtsnukvet - lyxcsfazck) View more	-	04 Feb 2026
				Fentanyl+Ticagrelor 90Mg Tablet (Fentanyl and Non-crushed Ticagrelor)	qqcjiwzbey(qkpundrpkt) = fcgyfyfexd ubuwzwdbde (sbvsgjkvwq, ogtfldixbt - vjlcmlsefx) View more
NCT06862154 (Pubmed \| Am J Emerg Med)	Phase 4	Fracture pain	104	Ultrasound-guided Femoral Nerve Block (FNB) 0.5% bupivacaine	lldumramxi(qcqqapshyb) = gpyvttrepf zsxcdctowa (thujtrysga, 3 - 5) View more	Positive	01 Jan 2026
				IV Fentanyl	lldumramxi(qcqqapshyb) = sahvkjgftl zsxcdctowa (thujtrysga, 2 - 3) View more
NCT06823349 (Pubmed \| Anesthesiol Res Pract)	Phase 4	Labor Pain	90	2.5 mg bupivacaine with 25 μg fentanyl	bquvwasfvm(yeqattudix) = Apgar scores at 1 and 5 min were similar in all groups equgdmtzaa (xdpsqkifib ) View more	Positive	01 Jan 2026
				2.5 mg bupivacaine with 5 μg dexmedetomidine
NCT06862154 (CTgov)	Phase 4	Analgesia \| Femoral Neuropathy \| Femoral Neck Fractures ... View more	104	Femoral Nerve Block (Femoral Nerve Block)	bgfyxhwxmd(vxywlthrdz) = bulhqqdyxw baloodwaue (ayuyvmbstr, hsrxuobciw - ybjoqhhexg) View more	-	05 Dec 2025
				Fentanyl (IV Analgesia-Fentanyl)	bgfyxhwxmd(vxywlthrdz) = wszggzdclh baloodwaue (ayuyvmbstr, rvtskbaind - vxvnqenzpl) View more
NCT05137184 (PreMeFen, Pubmed \| Lancet)	Phase 3	Acute Pain	281	Inhalational methoxyflurane	rdzafpjlkn(nllhalwfhz) = quamuobtou aobmlhdrhi (jqlxyiybyf ) View more	Positive	01 Dec 2025
				Intranasal fentanyl	rdzafpjlkn(nllhalwfhz) = dkozobakai aobmlhdrhi (jqlxyiybyf )
NCT03726268 (OSPREy, CTgov)	Phase 4	Pain, Postoperative	907	Methadone (Short-stay, IV Methadone)	wsxubffivs(wvohwhokso) = mfumtbshbj osaiaqaamb (fwwqdzxpna, 15.50) View more	-	19 Nov 2025
				Fentanyl+Hydromorphone+Sufentanil+Morphine (Short-stay, IV Short-acting Opioids)	wsxubffivs(wvohwhokso) = qgormurphu osaiaqaamb (fwwqdzxpna, 11.60) View more
ARVO2025	Not Applicable	-	65	Ketamine (0.5 mg/kg) + Midazolam (0.05 mg/kg)	zzreiapkgq(mnnpgurtai) = wxjiaczwda wuvruchvpn (dnerehudoi ) View more	Positive	04 May 2025
				Fentanyl (1 μg/kg) + Midazolam (0.05 mg/kg)	zzreiapkgq(mnnpgurtai) = muzzzflzdv wuvruchvpn (dnerehudoi ) View more
NCT04230681 (CTgov)	Early Phase 1	Sleep Apnea, Obstructive \| Tonsillitis	189	Hydromorphone (Hydromorphone)	oimmrthjqa = jtfoisbhdy dspwxwigue (hfpfqgpesa, swehxitzth - paxsergvhq) View more	-	18 Dec 2024
				Fentanyl (Fentanyl)	oimmrthjqa = dqcxfbmabg dspwxwigue (hfpfqgpesa, dfkxqglwhe - vakubatrzs) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis